Executive Summary
Investment highlights for NuBatt's nuclear technology company
Executive Summary
Investment Opportunity
NuBatt Pte. Ltd. ("NuBatt" or the "Company") is a Singapore-based advanced energy technology company developing next-generation nuclear voltaic power systems—batteries that convert radiation from radioisotopes into electricity. Unlike conventional batteries that degrade and require frequent recharging, NuBatt's technology delivers continuous power for up to decades without maintenance, replacement, or recharging.
The Company is seeking US$119 million in exchange for 30% equity to fund the commercialisation of its nuclear battery technology, establish isotope production capabilities, and scale operations globally.
The Problem
The world faces a convergence of critical energy challenges:
The NuBatt Solution
NuBatt is developing proprietary nuclear voltaic technology that addresses these challenges by converting radioactive decay energy directly into electricity. The Company's multi-platform approach includes:
| Product | Technology | Power Range | Operational Life |
|---|---|---|---|
| NuBatt-S1 | Betavoltaic (solid-state) | nW to μW | 30+ years |
| NuBatt-L1 | Liquid Transducer (alpha-voltaic) | μW to mW | 50-100+ years |
| NuBatt-P1 | Xenon Photovoltaic | Variable | Multi-decade |
| NuBatt-Q1 | Quantum Spherical | High efficiency | Multi-decade |
Key Differentiators:
- Never recharge: Continuous power output for up to decades
- Extreme environment operation: Functions in conditions where conventional batteries fail
- Safe and compliant: Dose rates well below IAEA limits (<0.1 μSv/h validated)
- Multiple isotope options: Not dependent on a single isotope source
Validation
NuBatt's technology has been validated through a completed feasibility study with DSO National Laboratories, Singapore's national defence research organisation:
Contract
PO62504138
Scope
Results
Full MCNP (Monte Carlo N-Particle) simulations validated shielding designs; dose rates confirmed at 4.3× below safety thresholds
Status
Successfully completed
The underlying technology platform could attract interest from major aerospace and defence organisations globally, demonstrating market demand for long-duration power solutions.
Business Model: Six Revenue Streams
NuBatt operates a diversified business model spanning six complementary revenue streams:
| Revenue Stream | 2027 | 2031 | Description |
|---|---|---|---|
| Nuclear Batteries | $5M | $1.2B | Core product sales to defence, aerospace, IoT, medical |
| Medical Isotopes | $30M | $600M | Production of diagnostic and therapeutic isotopes (Mo-99, Lu-177, Ac-225) |
| Industrial Isotopes | $10M | $350M | NDT, sterilisation, gauging applications |
| Nuclear Waste Recycling | — | $544M | Converting spent fuel into battery feedstock and isotopes |
| Advanced Carbon Materials | $3M | $80M | SiC wafers, nanodiamonds, carbon nano-onions from sustainable sources |
| Technology Licensing | $2M | $70M | Geographic and application-specific IP licensing |
| Total Revenue | $50M | $2.8B |
This multi-stream approach provides revenue diversification, creates supply chain synergies (waste recycling feeds battery production), and positions NuBatt across multiple high-growth markets.
Intellectual Property
NuBatt has assembled a strong intellectual property portfolio comprising 9 patent families:
Owned Patents (6 Singapore Applications):
- Liquid Transducer Radioisotope-Powered Systems
- Gaseous Xenon-Based Nuclear Voltaic Power Sources
- Noble Gas-Based Nuclear Voltaic Systems
- Liquid Xenon-Powered Nuclear Voltaic Systems
- Nuclear Voltaic System configurations
- Nuclear Voltaic Power-Source designs
The license from NDB Inc. is worldwide, perpetual, irrevocable, and sublicensable, with NuBatt owning all improvements independently. NuBatt holds right of first refusal on any future IP transfers.
Market Opportunity
NuBatt addresses multiple large and growing markets:
| Market Segment | Applications | Drivers |
|---|---|---|
| Defence & Aerospace | UAVs, satellites, remote sensors, submarines | Endurance requirements, energy independence |
| Medical Devices | Implantable devices, remote monitors | Aging population, device miniaturisation |
| Industrial IoT | Remote sensors, infrastructure monitoring | Billions of deployed devices, maintenance costs |
| Medical Isotopes | Diagnostic imaging, cancer therapy | 40M+ procedures annually, supply shortages |
| Clean Energy | Grid-independent power, remote installations | Decarbonisation, energy security |
The global nuclear battery market, medical isotope market, and industrial isotope market collectively represent tens of billions of dollars in addressable opportunity.
Financial Projections
Conservative financial projections based on the Company's DCF model:
| Year | Revenue | EBITDA | EBITDA Margin |
|---|---|---|---|
| 2027 | $50M | $12M | 23.9% |
| 2028 | $201M | $85M | 42.1% |
| 2029 | $661M | $300M | 45.4% |
| 2030 | $1.41B | $621M | 44.0% |
| 2031 | $2.85B | $1.23B | 43.3% |
Revenue CAGR (2027-2031)
~170%
Target EBITDA margin at scale
Path to profitability
Exit opportunity
IPO targeted for 2030 at $10B+ valuation
Investment Terms
| Term | Details |
|---|---|
| Securities Offered | Ordinary Shares |
| Amount Sought | US$119,000,000 |
| Equity Offered | 30% |
| Pre-Money Valuation | ~US$397,000,000 |
| Post-Money Valuation | ~US$516,000,000 |
| Structure | Single Close |
| Minimum Investment | To be determined |
Use of Proceeds
The Company intends to allocate the investment proceeds as follows:
| Category | Allocation | Purpose |
|---|---|---|
| Facility & Equipment | ~45% | Manufacturing facility (Singapore or strategic global location TBD), cleanroom, hot cells, production equipment |
| R&D & Prototyping | ~20% | Product development, prototype manufacturing, testing and validation |
| Team Expansion | ~15% | Engineering, regulatory affairs, business development, operations |
| Regulatory & Licensing | ~10% | Nuclear licensing, IAEA compliance, export certifications |
| Working Capital | ~10% | Isotope procurement, operational expenses, contingency |
Strategic Growth Opportunities
Beyond the core battery and isotope business, NuBatt has identified two strategic growth opportunities that provide additional upside for investors:
NuRTG (Radioisotope Thermoelectric Generator):
- Medium to high power output (watts to kilowatts)
- Target markets: Space missions, remote installations
- 10+ years continuous operation
- Development to commence with this funding
Why NuBatt, Why Now
Technology Readiness: Core technology validated through DSO Singapore feasibility study with successful MCNP simulations and safety compliance demonstrated.
Market Timing: Defence modernisation programmes globally are driving demand for long-endurance power solutions. Medical isotope supply chains face critical shortages. IoT proliferation is creating unprecedented demand for maintenance-free power.
Regulatory Environment: Nuclear regulatory frameworks are evolving to accommodate advanced nuclear technologies, with Singapore providing a stable, business-friendly base.
Competitive Position: NuBatt's multi-platform, multi-isotope approach provides flexibility that single-technology competitors cannot match. Strong IP portfolio protects core innovations.
Team: Experienced leadership with deep expertise in nuclear technology, semiconductor physics, and commercial development.
Corporate Structure
| Legal Entity | NuBatt Pte. Ltd. |
| Incorporation | Republic of Singapore |
| Company Registration | 202342218N |
| Registered Office | 16 Raffles Quay, #41-01, Hong Leong Building, Singapore 048581 |
NuBatt is a Singapore entity with no legacy liabilities. The Company operates independently with its own intellectual property, management, and operations.
Summary
NuBatt represents a compelling investment opportunity at the intersection of advanced energy technology, defence applications, and the global transition to sustainable power sources. With validated technology, a strong IP portfolio, diversified revenue streams, and a clear path to scale, the Company is positioned to become a leader in the emerging nuclear battery and isotope markets.
The Company is seeking US$119 million for 30% equity to accelerate commercialisation and capture this significant market opportunity.
For inquiries, please contact:
NuBatt Pte. Ltd. 16 Raffles Quay, #41-01 Hong Leong Building Singapore 048581 Email: info@nubatt.com